REGENERON PHARMACEUTICALS, INC. Insider Trading for August 2015
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in REGENERON PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in REGENERON PHARMACEUTICALS, INC. for August 2015.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 270.43 | 10,000 | 2,704,300 | 30,000 | |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 179.13 | 14,625 | 2,619,776 | 29,250 | |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 52.03 | 8,000 | 416,240 | 6,079 | |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 52.03 | 23,000 | 1,196,690 | 14,079 | |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 30.63 | 4,736 | 145,064 | 0 | |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 578.63 | 1,500 | 867,945 | 15,821 | 17.3 K to 15.8 K (-8.66 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 577.75 | 2,258 | 1,304,560 | 17,321 | 19.6 K to 17.3 K (-11.53 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 576.65 | 2,004 | 1,155,607 | 19,579 | 21.6 K to 19.6 K (-9.29 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 575.47 | 700 | 402,829 | 21,583 | 22.3 K to 21.6 K (-3.14 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 574.75 | 900 | 517,275 | 22,283 | 23.2 K to 22.3 K (-3.88 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 573.64 | 2,717 | 1,558,580 | 23,183 | 25.9 K to 23.2 K (-10.49 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 572.60 | 2,800 | 1,603,280 | 25,900 | 28.7 K to 25.9 K (-9.76 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 571.54 | 5,598 | 3,199,481 | 28,700 | 34.3 K to 28.7 K (-16.32 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 570.63 | 3,603 | 2,055,980 | 34,298 | 37.9 K to 34.3 K (-9.51 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 569.63 | 1,405 | 800,330 | 37,901 | 39.3 K to 37.9 K (-3.57 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 2,146 | 1,243,285 | 39,306 | 41.5 K to 39.3 K (-5.18 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 250 | 144,838 | 41,452 | 41.7 K to 41.5 K (-0.60 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 30.63 | 4,736 | 145,064 | 41,702 | 37 K to 41.7 K (+12.81 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 3,755 | 2,175,459 | 36,966 | 40.7 K to 37 K (-9.22 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 718 | 415,973 | 40,721 | 41.4 K to 40.7 K (-1.73 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 52.03 | 8,000 | 416,240 | 41,439 | 33.4 K to 41.4 K (+23.92 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 10,795 | 6,254,083 | 33,439 | 44.2 K to 33.4 K (-24.40 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 2,065 | 1,196,358 | 44,234 | 46.3 K to 44.2 K (-4.46 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 52.03 | 23,000 | 1,196,690 | 46,299 | 23.3 K to 46.3 K (+98.72 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 5,210 | 3,018,414 | 23,299 | 28.5 K to 23.3 K (-18.27 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 4,521 | 2,619,241 | 28,509 | 33 K to 28.5 K (-13.69 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 179.13 | 14,625 | 2,619,776 | 33,030 | 18.4 K to 33 K (+79.46 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 2,749 | 1,592,633 | 18,405 | 21.2 K to 18.4 K (-13.00 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 4,667 | 2,703,826 | 21,154 | 25.8 K to 21.2 K (-18.07 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 270.43 | 10,000 | 2,704,300 | 25,821 | 15.8 K to 25.8 K (+63.21 %) |
| Aug 12 2015 | REGN | REGENERON PHARMACE ... | POON CHRISTINE A | Director | Option Exercise | M | 273.67 | 470 | 128,625 | 12,280 | |
| Aug 12 2015 | REGN | REGENERON PHARMACE ... | POON CHRISTINE A | Director | Sell | S | 564.17 | 12 | 6,770 | 790 | 802 to 790 (-1.50 %) |
| Aug 12 2015 | REGN | REGENERON PHARMACE ... | POON CHRISTINE A | Director | Sell | S | 564.16 | 100 | 56,416 | 802 | 902 to 802 (-11.09 %) |
| Aug 12 2015 | REGN | REGENERON PHARMACE ... | POON CHRISTINE A | Director | Payment of Exercise | F | 574.57 | 223 | 128,129 | 902 | 1.1 K to 902 (-19.82 %) |
| Aug 12 2015 | REGN | REGENERON PHARMACE ... | POON CHRISTINE A | Director | Buy | M | 273.67 | 470 | 128,625 | 1,125 | 655 to 1.1 K (+71.76 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | GILMAN ALFRED G | Director | Option Exercise | M | 57.11 | 5,000 | 285,550 | 0 | |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | GILMAN ALFRED G | Director | Sell | S | 593.00 | 62 | 36,766 | 8,912 | 9 K to 8.9 K (-0.69 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | GILMAN ALFRED G | Director | Sell | S | 592.53 | 138 | 81,769 | 8,974 | 9.1 K to 9 K (-1.51 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | GILMAN ALFRED G | Director | Sell | S | 591.39 | 200 | 118,278 | 9,112 | 9.3 K to 9.1 K (-2.15 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | GILMAN ALFRED G | Director | Sell | S | 590.37 | 900 | 531,333 | 9,312 | 10.2 K to 9.3 K (-8.81 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | GILMAN ALFRED G | Director | Sell | S | 589.73 | 400 | 235,892 | 10,212 | 10.6 K to 10.2 K (-3.77 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | GILMAN ALFRED G | Director | Sell | S | 588.33 | 400 | 235,332 | 10,612 | 11 K to 10.6 K (-3.63 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | GILMAN ALFRED G | Director | Sell | S | 587.55 | 400 | 235,020 | 11,012 | 11.4 K to 11 K (-3.51 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | GILMAN ALFRED G | Director | Sell | S | 586.49 | 200 | 117,298 | 11,412 | 11.6 K to 11.4 K (-1.72 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | GILMAN ALFRED G | Director | Sell | S | 585.35 | 800 | 468,280 | 11,612 | 12.4 K to 11.6 K (-6.45 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | GILMAN ALFRED G | Director | Sell | S | 584.52 | 800 | 467,616 | 12,412 | 13.2 K to 12.4 K (-6.06 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | GILMAN ALFRED G | Director | Sell | S | 583.43 | 400 | 233,372 | 13,212 | 13.6 K to 13.2 K (-2.94 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | GILMAN ALFRED G | Director | Sell | S | 582.15 | 300 | 174,645 | 13,612 | 13.9 K to 13.6 K (-2.16 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | GILMAN ALFRED G | Director | Buy | M | 57.11 | 5,000 | 285,550 | 13,912 | 8.9 K to 13.9 K (+56.10 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Terifay Robert J | SVP Commercial | Option Exercise | M | 30.63 | 29,236 | 895,499 | 0 | |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Terifay Robert J | SVP Commercial | Option Exercise | M | 30.63 | 3,264 | 99,976 | 0 | |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Terifay Robert J | SVP Commercial | Sell | S | 593.66 | 800 | 474,928 | 23,293 | 24.1 K to 23.3 K (-3.32 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Terifay Robert J | SVP Commercial | Sell | S | 592.40 | 23 | 13,625 | 24,093 | 24.1 K to 24.1 K (-0.10 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Terifay Robert J | SVP Commercial | Sell | S | 591.75 | 957 | 566,305 | 24,116 | 25.1 K to 24.1 K (-3.82 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Terifay Robert J | SVP Commercial | Sell | S | 590.57 | 2,486 | 1,468,157 | 25,073 | 27.6 K to 25.1 K (-9.02 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Terifay Robert J | SVP Commercial | Sell | S | 589.76 | 2,542 | 1,499,170 | 27,559 | 30.1 K to 27.6 K (-8.44 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Terifay Robert J | SVP Commercial | Sell | S | 588.55 | 2,126 | 1,251,257 | 30,101 | 32.2 K to 30.1 K (-6.60 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Terifay Robert J | SVP Commercial | Sell | S | 587.35 | 2,482 | 1,457,803 | 32,227 | 34.7 K to 32.2 K (-7.15 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Terifay Robert J | SVP Commercial | Sell | S | 585.22 | 2,007 | 1,174,537 | 34,709 | 36.7 K to 34.7 K (-5.47 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Terifay Robert J | SVP Commercial | Payment of Exercise | F | 588.64 | 14,292 | 8,412,843 | 36,716 | 51 K to 36.7 K (-28.02 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Terifay Robert J | SVP Commercial | Payment of Exercise | F | 588.64 | 1,521 | 895,321 | 51,008 | 52.5 K to 51 K (-2.90 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Terifay Robert J | SVP Commercial | Buy | M | 30.63 | 29,236 | 895,499 | 52,529 | 23.3 K to 52.5 K (+125.51 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Terifay Robert J | SVP Commercial | Buy | M | 30.63 | 3,264 | 99,976 | 23,293 | 20 K to 23.3 K (+16.30 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | SVP & General Mgr I ... | Option Exercise | M | 30.63 | 4,605 | 141,051 | 53,381 | |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | SVP & General Mgr I ... | Option Exercise | M | 21.25 | 4,095 | 87,019 | 0 | |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | SVP & General Mgr I ... | Sell | S | 586.24 | 1,128 | 661,279 | 0 | 1.1 K to 0 (-100.00 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | SVP & General Mgr I ... | Sell | S | 585.02 | 900 | 526,518 | 1,128 | 2 K to 1.1 K (-44.38 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | SVP & General Mgr I ... | Sell | S | 583.89 | 1,000 | 583,890 | 2,028 | 3 K to 2 K (-33.03 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | SVP & General Mgr I ... | Sell | S | 582.12 | 1,000 | 582,120 | 3,028 | 4 K to 3 K (-24.83 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | SVP & General Mgr I ... | Payment of Exercise | F | 588.64 | 2,035 | 1,197,882 | 4,028 | 6.1 K to 4 K (-33.56 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | SVP & General Mgr I ... | Payment of Exercise | F | 588.64 | 147 | 86,530 | 6,063 | 6.2 K to 6.1 K (-2.37 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | SVP & General Mgr I ... | Buy | M | 21.25 | 4,095 | 87,019 | 6,210 | 2.1 K to 6.2 K (+193.62 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | SVP & General Mgr I ... | Payment of Exercise | F | 588.64 | 2,251 | 1,325,029 | 2,115 | 4.4 K to 2.1 K (-51.56 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | SVP & General Mgr I ... | Payment of Exercise | F | 588.64 | 239 | 140,685 | 4,366 | 4.6 K to 4.4 K (-5.19 %) |
| Aug 07 2015 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | SVP & General Mgr I ... | Buy | M | 30.63 | 4,605 | 141,051 | 4,605 | 0 to 4.6 K |
| Aug 06 2015 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Option Exercise | M | 272.70 | 4,000 | 1,090,800 | 66,000 | |
| Aug 06 2015 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 593.38 | 2,100 | 1,246,098 | 7,099 | 9.2 K to 7.1 K (-22.83 %) |
| Aug 06 2015 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 592.36 | 1,500 | 888,540 | 9,199 | 10.7 K to 9.2 K (-14.02 %) |
| Aug 06 2015 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Sell | S | 591.78 | 400 | 236,712 | 10,699 | 11.1 K to 10.7 K (-3.60 %) |
| Aug 06 2015 | REGN | REGENERON PHARMACE ... | Landry Robert E | SVP Finance & CFO | Buy | M | 272.70 | 4,000 | 1,090,800 | 11,099 | 7.1 K to 11.1 K (+56.35 %) |
| Aug 05 2015 | REGN | REGENERON PHARMACE ... | McCorkle Douglas S | VP Controller and A ... | Option Exercise | M | 270.43 | 4,800 | 1,298,064 | 15,000 | |
| Aug 05 2015 | REGN | REGENERON PHARMACE ... | McCorkle Douglas S | VP Controller and A ... | Option Exercise | M | 270.43 | 200 | 54,086 | 19,800 | |
| Aug 05 2015 | REGN | REGENERON PHARMACE ... | McCorkle Douglas S | VP Controller and A ... | Sell | S | 585.51 | 4,800 | 2,810,448 | 4,945 | 9.7 K to 4.9 K (-49.26 %) |
| Aug 05 2015 | REGN | REGENERON PHARMACE ... | McCorkle Douglas S | VP Controller and A ... | Buy | M | 270.43 | 4,800 | 1,298,064 | 9,745 | 4.9 K to 9.7 K (+97.07 %) |
| Aug 05 2015 | REGN | REGENERON PHARMACE ... | McCorkle Douglas S | VP Controller and A ... | Sell | S | 586.00 | 200 | 117,200 | 4,945 | 5.1 K to 4.9 K (-3.89 %) |
| Aug 05 2015 | REGN | REGENERON PHARMACE ... | McCorkle Douglas S | VP Controller and A ... | Buy | M | 270.43 | 200 | 54,086 | 5,145 | 4.9 K to 5.1 K (+4.04 %) |
| Aug 05 2015 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Option Exercise | M | 57.11 | 5,000 | 285,550 | 5,000 | |
| Aug 05 2015 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Sell | S | 595.44 | 500 | 297,720 | 1,187 | 1.7 K to 1.2 K (-29.64 %) |
| Aug 05 2015 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Sell | S | 593.64 | 2,000 | 1,187,280 | 1,687 | 3.7 K to 1.7 K (-54.24 %) |
| Aug 05 2015 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Sell | S | 590.17 | 1,000 | 590,170 | 3,687 | 4.7 K to 3.7 K (-21.34 %) |
| Aug 05 2015 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Sell | S | 584.07 | 1,500 | 876,105 | 4,687 | 6.2 K to 4.7 K (-24.24 %) |
| Aug 05 2015 | REGN | REGENERON PHARMACE ... | Tessier-Lavigne Marc | Director | Buy | M | 57.11 | 5,000 | 285,550 | 6,187 | 1.2 K to 6.2 K (+421.23 %) |
| Aug 05 2015 | REGN | REGENERON PHARMACE ... | GOLDSTEIN JOSEPH L | Director | Sell | S | 586.00 | 2,000 | 1,172,000 | 14,000 | 16 K to 14 K (-12.50 %) |
| Aug 03 2015 | REGN | REGENERON PHARMACE ... | GILMAN ALFRED G | Director | Option Exercise | C | 0.00 | 8,912 | 0 | 0 | |
| Aug 03 2015 | REGN | REGENERON PHARMACE ... | GILMAN ALFRED G | Director | Buy | C | 0.00 | 8,912 | 0 | 8,912 | 0 to 8.9 K |